First in Human Study of TORL-1-23 in Participants With Advanced Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

November 17, 2021

Primary Completion Date

August 31, 2026

Study Completion Date

November 15, 2026

Conditions
Advanced Solid TumorOvarian CancerEndometrial CancerNSCLC
Interventions
DRUG

TORL-1-23

antibody drug conjugate (ADC)

Trial Locations (14)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

16247

RECRUITING

St. Vincent's Hospital, The Catholic University of Korea, Suwon

22031

RECRUITING

Virginia Cancer Specialists, Fairfax

40536

RECRUITING

University of Kentucky Medical Center, Lexington

44195

RECRUITING

Cleveland Clinic, Cleveland

55455

RECRUITING

University of Minnesota, Minneapolis

55905

RECRUITING

Mayo Clinic in Rochester, Rochester

75702

RECRUITING

Sarah Cannon Research Institute Texas Oncology, Tyler

90095

RECRUITING

UCLA - JCCC Clinical Research Unit, Los Angeles

92835

RECRUITING

Providence Medical Foundation, Fullerton

03080

RECRUITING

Seoul National University Hospital, Seoul

03723

RECRUITING

Severance Hospital, Seoul

05505

RECRUITING

Asan Medical Center, Seoul

06351

RECRUITING

Samsung Medical Center, Seoul

All Listed Sponsors
collaborator

Translational Research in Oncology

OTHER

lead

TORL Biotherapeutics, LLC

INDUSTRY